Ortho Regenerative Technologies (CSE:ORTH.CN) announced that a peer-reviewed article entitled, “Freeze-Dried [Ortho-R] Injectable Surgical Implants for Meniscus Repair: Pilot Feasibility Studies in Ovine Models,” has been published in the current issue of Regenerative Medicine and Therapeutics.
Clinical management of meniscus tears often involves partial meniscectomy, which can lead to osteoarthritis due to the tissue’s limited healing response. The purpose of the study reported in the article was to assess the feasibility of using Ortho RTi’s Ortho-R hybrid implants to improve meniscus repair in ovine models.
The article said that complete repair and seamless repair tissue integration were observed in one-of-four [Ortho-R] treated defects in the first study after three months and in one-of-two [Ortho-R] treated defects in the second study after six weeks, while there was no healing with platelet rich plasma or wrapping alone.
“These pilot feasibility studies demonstrated that [Ortho-R] injectable implants display some potential to improve meniscus repair outcomes in preclinical models and could overcome some of the current limitations of meniscus repair by assisting in restoring meniscus structure and function,” according to the article.
In a statement, Ortho RTi executive chairman and CEO, Dr. Brent Norton, said this is the second paper published this month that has shown the strong potential that the company’s proprietary biopolymer platform holds for improving the success rate of soft tissue sports injury surgeries.
An abstract of the article can be accessed here.
